Algernon Pharmaceuticals Announces up to $5.0 Million Private Placement Offering of Special Warrants ... 30, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc ... CEO Algernon Pharmaceuticals Inc. Algernon Pharmaceuticals is a clinical stage pharmaceutical development company focused on the areas of non–alcoholic steatohepatitis (NASH), chronic kidney disease (CKD), inflammatory bowel disease (IBD) and idiopathic Pulmonary fibrosis.
Ambassador (Rtd) Howard InvestorsHub NewsWire - 4/13/2020 9:44:01 AM: Algernon Announces Filing of U.S. FDA Pre-IND Meeting Request for Ifenprodil Coronavirus Trial, Expanded Access, and Emergency InvestorsHub NewsWire - 3/13/2020 8:40:22 AM
CONTACT INFORMATION. Algernon Pharmaceuticals Inc (OTCQB:AGNPF) has received US Food and Drug Administration clearance for its planned multinational study of lead drug NP-120, known as Ifenprodil, as a potential therapeutic treatment for patients with the COVID-19 disease.
Algernon has filed new intellectual property rights globally for NP-120 (Ifenprodil) for the treatment of respiratory diseases and is working to develop a proprietary injectable and slow release formulation. Today we have the CEO of Algernon Pharmaceuticals (CSE: AGN) (OTCQB: AGNPF) Mr. Christopher Moreau sitting down with us for an exclusive interview regarding the company’s operations surrounding Covid-19.EI) Mr. Moreau, for investors that are not very familiar with Algernon Pharmaceuticals, could you tell us the vision of Algernon and how it all began? This is where the expertise amassed at Algernon Pharmaceuticals comes into play. Algernon Pharmaceuticals Announces up to $5.0 Million Private Placement Offering of Special Warrants. According to Christopher J. Moreau, CEO of Algernon Pharmaceuticals, IPF has an … Email Print ... About Algernon Pharmaceuticals Inc. Algernon … Moreau talks about how big this milestone is for the company and how the study is to be conducted. Algernon Pharmaceuticals announced clearance from the US FDA for the Study of the Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Confirmed COVID-19 Infected Hospitalized Patients. Algernon Receives Positive Feedback from U.S. FDA for Ifenprodil COVID-19 Human Trial; Appoints U.S. Real-time discussion about Algernon Pharmaceuticals Inc. (AGN.CN) on CEO.CA, an investment chat community for Canada's small cap markets
Algernon Pharmaceuticals Inc. (CSE: AGN-OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive Vancouver with major news for the company that they have received clearance from the U.S. FDA for its multinational Phase 2b/3 study of Ifenprodil as a potential treatment for COVID-19.